Paris, France

Pierre-Etienne Chabrier De Lassauniere



 

Average Co-Inventor Count = 3.3

ph-index = 11

Forward Citations = 285(Granted Patents)


Location History:

  • Bleriot, FR (2008)
  • Paris, FR (1992 - 2018)

Company Filing History:


Years Active: 1992-2018

Loading Chart...
Loading Chart...
Loading Chart...
35 patents (USPTO):Explore Patents

Title: Pierre-Etienne Chabrier de Lassauniere: Innovator in Therapeutics

Introduction: Pierre-Etienne Chabrier de Lassauniere is a renowned inventor based in Paris, France, celebrated for his contributions to the pharmaceutical field. With an impressive portfolio of 33 patents, Lassauniere has made significant strides in the development of therapeutic agents.

Latest Patents: Among his latest innovations, Lassauniere has developed thiazole derivatives aimed at treating dyskinesias caused by chemical treatments. This invention focuses on the use of thiazole derivatives with a general formula for preparing medications that address the prevention and treatment of dyskinesias. Furthermore, he has devised a method for quantifying a cholinergic neurotoxin in a sample, demonstrating his commitment to advancing medical science through his inventive processes.

Career Highlights: Lassauniere has held positions in prestigious organizations such as Société de Conseils de Recherches et d'Applications Scientifiques (SCRAS) and Ipsen Pharma S.A.S., where he utilized his expertise to drive innovation in therapeutic research and development.

Collaborations: Throughout his career, Lassauniere has collaborated with notable peers, such as Serge Auvin and Jeremiah Harnett. These partnerships have propelled his research efforts and contributed to the success of his inventions in the scientific community.

Conclusion: Pierre-Etienne Chabrier de Lassauniere stands out as a visionary inventor whose work continues to influence the fields of pharmacology and toxicology. His patents reflect a dedication to improving health outcomes and enhancing our understanding of complex biological interactions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…